ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer

Chen, Shiyun; Gou, Miaomiao; Yan, Huan; Fan, Mengjiao; Pan, Yuting; Fan, Runjia; Qian, Niansong*; Dai, Guanghai*南方医科大学
DISEASE MARKERS2021-6-22DOI: 10.1155/2021/6639366
13被引5阅读
引用收藏
分享

摘要

Background. Nowadays, PD-1/PD-L1 inhibitors are widely used to treat various malignant tumors. However, during the immunotherapy in a few patients, a flare-up of tumor growth occurred. This new pattern of progression is called hyperprogressive disease (HPD). Patients and Methods. The retrospective study included 377 patients with various malignant tumors treated with PD-1 inhibitors (nivolumab or pembrolizumab) in the Chinese PLA General Hospital from January 2015 to January 2019. Clinicopathologic variables, tumor growth rate (TGR), and treatment outcomes were analyzed in patients with pan-cancer treated with PD-1 inhibitors. HPD was defined as the difference of TGR before and during immunotherapy exceeding 50%. Results. In 38 of 377 patients (10.08%), HPD occurred after treatment with PD-1 inhibitors. Patients with HPD had lower overall survival (OS) than those without HPD (median OS, 3.6months (95% CI, 3.0-4.2) vs. 7.3 months (95% CI, 5.9-8.7); P < 0.01). Factors related to HPD include more than 2 metastatic sites, ECOG performance status >= 2, hepatic metastases, and lactate dehydrogenase level greater than normal upper limit. KRAS status was significantly associated with HPD in patients with colorectal cancer. In the exploratory predictors' analysis, the rapid increase of characteristic tumor markers (such as CEA in colorectal cancer, CA199 in pancreatic cancer and cholangiocarcinoma) within one month was found to be associated with the occurrence of HPD. Conclusions. HPD was developed with different rates in a variety of malignant tumor patients treated with PD-1 inhibitors and related to some clinicopathological features and poor prognosis. Tumor markers, especially CA199, might be served as early predictors of HPD.

学科与关键词

关键词
OPEN-LABELINVESTIGATORS CHOICEADVANCED MELANOMACELL CARCINOMANIVOLUMABPEMBROLIZUMABCHEMOTHERAPYSURVIVALTHERAPYPHASE-3
相关
加载中…
  • The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.
    Wang, Xueping; Wang, Fang; Zhong, Mengjun; Yarden, Yosef; Fu, Liwu*Molecular Cancer, 2020, 19(1): 81.
  • Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy
    Zhang, Lu*; Wu, Lingeng; Chen, Qiuying; Zhang, Bin; Liu, Jing; Liu, Shuyi; Mo, Xiaokai; Li, Minmin; Chen, Zhuozhi; Chen, Luyan; You, Jingjing; Jin, Zhe; Chen, Xudong*; Zhou, Zejian*; Zhang, Shuixing*ECLINICALMEDICINE, 2021, 31: 100673.被引 23
  • Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors
    Xiao, Lu-Shan; Li, Qi-Mei; Hu, Cheng-Yi; Cui, Hao; Hong, Chang; Huang, Chao-Yi; Li, Rui-Ning; Dong, Zhong-Yi; Zhu, Hong-Bo; Liu, Li*Annals of Palliative Medicine, 2021, 10(11): 11244-+.被引 7
查看全部 →

发表信息

论文状态
公开发表
期刊
DISEASE MARKERS
发表日期
2021-06-22
卷期
第 2021 卷
页码
6639366
DOI
10.1155/2021/6639366
语言
ENGLISH
期刊收录
NSL
期刊等级
4区
成果收录
SCIE

作者

  • C

    Chen, Shiyun (第一作者)

    chinese peoples liberat army gen hosp

  • G

    Gou, Miaomiao

    chinese peoples liberat army gen hosp

查看全部 8 位作者收起作者
  • Y

    Yan, Huan

    chinese peoples liberat army gen hosp

  • F

    Fan, Mengjiao

    chinese peoples liberat army gen hosp

  • P

    Pan, Yuting

  • F

    Fan, Runjia

  • Q

    Qian, Niansong (通讯)

    chinese peoples liberat army gen hosp · 2 · southern med univ

  • D

    Dai, Guanghai (通讯)

    chinese peoples liberat army gen hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417